Cathie Wood’s ARK ETFs shuffle healthcare and tech stock holdings

Cathie Wood’s ARK ETFs have made their daily trades for Wednesday, June 25th, 2025, with a significant focus on healthcare and technology stocks. The trades included both substantial acquisitions and divestitures, reflecting ARK’s ongoing strategy to capitalize on market opportunities and emerging trends.

Leading the buys for the day was ARK’s purchase of 89345 shares of gene editing company BEAM Therapeutics Inc (NASDAQ:BEAM) through its ARKK ETF, totaling $1,532,266. This investment continues a recent trend, as ARK has been actively increasing its position in BEAM over the past week, signaling strong confidence in the company’s long-term potential.

ARK also bolstered its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP), buying 5955 shares valued at $278,574. This genetic medicines company, alongside BEAM, represents ARK’s deepening investment in the revolutionary CRISPR-Cas9 gene-editing technology.

In the technology sector, ARK showed a notable interest in e-commerce by purchasing a total of 36058 shares of Shopify Inc (NYSE:NASDAQ:SHOP) across three ETFs—ARKK, ARKW, and ARKF—with a combined dollar value of $4,125,756. This move highlights ARK’s continued bullish stance on Shopify’s growth prospects in the ever-expanding online retail space.

Another significant tech buy included 64344 shares of Nextdoor Holdings Inc (NYSE:KIND) through ARKW, amounting to $102,306. This local social networking platform has been receiving increased attention from ARK, indicating a potential strategic play on hyperlocal online ecosystems.

Toast Inc (NYSE:TOST) also saw a sizable investment from ARK, with 21953 shares bought across ARKW and ARKF ETFs, totaling $980,640. Toast’s cloud-based software for the restaurant industry seems to align with ARK’s thematic investment in innovative service models.

In the biotechnology space, ARK purchased 11770 shares of Twist Bioscience Corp (NASDAQ:TWST), valued at $421,954, and 50736 shares of Veracyte Inc (NASDAQ:VCYT) for $1,363,783. Both companies have been part of ARK’s portfolio, with consistent buying indicating a long-term conviction in their genomic and diagnostic technologies.

On the sell side, ARK divested a considerable number of shares in Robinhood Markets Inc (NASDAQ:HOOD), selling 55949 shares through ARKK for a total of $4,588,377. This sale represents a significant shift in ARK’s position on the financial services platform, which has seen a mix of buys and sells over recent weeks.

Smaller sales included 50 shares of Magna International Inc (NYSE:MGA) and 100 shares of UiPath Inc (NYSE:PATH) through the ARKQ ETF, with values of $1,880 and $1,251, respectively. These sales might indicate minor portfolio adjustments rather than a change in ARK’s overall investment thesis for these companies.

Investors and market watchers closely monitor ARK’s trades, as Cathie Wood’s ETFs are known for their forward-looking investment strategies, particularly in disruptive innovation sectors. Today’s trades underscore ARK’s dynamic and responsive approach to market developments, with a clear emphasis on healthcare and technology as areas poised for significant growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.